Johnson & Johnson

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-07-09 pm EDT			5-day change	1st Jan Change
156.28 ^USD	+0.31%		+0.23%	+8.06%

Jul. 09	Major deals involving U.S. drugmakers and biotechs over the past decade	RE
Jul. 09	Transgene SA Announces Board Changes	CI

Johnson & Johnson Unit Receives Positive EU Opinion for Imbruvica Indication Extension

Published on 06/20/2025 at 12:35

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Johnson & Johnson

Major deals involving U.S. drugmakers and biotechs over the past decade	Jul. 09	RE
Transgene SA Announces Board Changes	Jul. 09	CI
Johnson & Johnson's Q2 Earnings Call Likely to Focus on Guidance, Tariff Impact, BofA Says	Jul. 09	MT
Company earnings: key dates for next week	Jul. 09
Trump says pharmaceutical tariffs could reach 200%	Jul. 08	RE
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	Jul. 08	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	Jul. 08	MT
Sector Update: Health Care Stocks Steady Premarket Tuesday	Jul. 08	MT
Volatility as a Strategy	Jul. 08
J&J: seeks FDA approval for Caplyta for schizophrenia	Jul. 08	CF
Johnson & Johnson Announces the Submission of A Supplemental New Drug Application to the U.S. Food and Drug Administration Based Upon Long-Term Data Evaluating the Safety and Efficacy of Caplyta (Lumateperone) for the Prevention of Relapse in Schizophrenia	Jul. 08	CI
Johnson & Johnson Submits Supplemental NDA for Schizophrenia Treatment Caplyta	Jul. 08	MT
Nanobiotix: NBTXR3 device reclassified as a drug	Jul. 08	CF
Nanobiotix Reports Regulatory Harmonization, New Composition of Matter Patent Filed for JNJ-1900	Jul. 07	MT
Johnson & Johnson Unit Submits EMA Application to Extend Indication of Akeega for Prostate Cancer	Jul. 03	MT
J&J Unit Seeks Indication Extension for Cancer Drug Combo in EU	Jul. 03	MT
US FDA approves Regeneron's blood cancer therapy	Jul. 02	RE
Health Rounds: 3D printed insulin-producing cells show promise for type 1 diabetes in lab tests	Jul. 02	RE
Orthocell Limited Appoints Adam Wood as Chief Commercial Officer	Jul. 02	CI
US FDA to revise ADHD stimulants labels to warn of weight loss risk in children under 6	Jun. 30	RE
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies (June 27)	Jun. 30	RE
Vicarious Surgical Inc. Announces Changes to Its Board	Jun. 30	CI
Formycon Selects Ratiopharm as Secondary Commercialization Partner for Fymskina in Germany	Jun. 26	MT
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug	Jun. 24	RE
Compass shares hits record low after depression drug fails to impress	Jun. 23	RE

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.1%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (35.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; At the end of 2024, Johnson & Johnson has 64 manufacturing facilities located in the United States (23), North America (7), Europe (21), Africa and Asia/Pacific (13). The United States accounts for 56.6% of net sales.

Employees

138,100

Sector

Pharmaceuticals

Calendar

Jul. 16 - Q2 2025 Earnings Release

More about the company